The Company's other therapeutic candidates include MKC-1, an oral cell-cycle regulator with activity against the mTOR pathway currently in multiple Phase 2 clinical trials for cancer, and ENMD-1198, a novel antimitotic agent
currently in Phase 1 studies in advanced cancers.
Diabetes, renal failure, duration of stent placement, small reference vessel diameter, complex lesions, low ejection fraction, local hypersensitivity reactions, position of the stent relative to plaque, type and dose of antimitotic agent
have also been identified as contributory factors (8,10-13).
The alkaloid and antimitotic agent
colchicine has shown mixed effects on the progression of fibrosis, ascites, esophageal varices, portal vein pressure, functional status, and mortality in cirrhosis patients, but no studies had assessed its effect against HCC, the investigators said.